mdxhealth Strong preliminary Q2 results trigger guidance upgrade

mdxhealth's preliminary 2Q24 results feature a continued strong uptake in revenues to $ 22.2m (+32% y/y). We presume the new germline test has started contributing revenue as of Q2 as planned, and on the back of strong growth prospects management again raised its FY24 revenue guidance to $ 85-87m i.e., 23% growth y/y. The company expresses confidence in reaching adjusted EBITDA profitability in 1H25. We maintain our $ 6 TP and re-iterate our Buy rating.